State Street Holds 5.6% Of Recursion Pharmaceuticals On A Passive Basis

The position covered 30,001,137 common shares as of September 30, 2026, rather than a stake bought to influence control.

Share
State Street Holds 5.6% Of Recursion Pharmaceuticals On A Passive Basis

State Street reported a 5.6% stake in Recursion Pharmaceuticals, a clinical-stage drug developer using artificial intelligence and automated laboratories, in a passive ownership disclosure filed Tuesday. The position covered 30,001,137 common shares as of September 30, 2026.

Passive Ownership, Shared Voting Power

State Street certified that it bought and held the securities as part of its ordinary business, rather than with the aim or effect of changing Recursion's control.

Its shared voting power covered 28,700,743 shares. State Street reported sole voting power of zero and shared power to dispose of all 30,001,137 shares.

AI Laboratories And Drug Partnerships

Recursion's Recursion Operating System spans the generation of biological data, small-molecule design and clinical-trial work. Its automated laboratories can conduct more than 2 million experiments a week, according to its annual report for 2025.

That report described an internal pipeline of five clinical and two preclinical programs focused on oncology and rare diseases, including REC-4881 for familial adenomatous polyposis.

Recursion also works with Roche and Genentech, Sanofi, Bayer and Merck KGaA on funded discovery efforts in oncology, neuroscience and immunology. Its annual report said partner upfront and milestone payments had exceeded $500 million.

Sources

More on Recursion Pharmaceuticals

All Recursion Pharmaceuticals (RXRX) coverage →